Regenerative Medicine in Action: Turn Bio's ERA Technology Reprograms Skin Cells

ERA reprogramming technology significantly reduced oxidative stress, matrix metalloproteinases (MMPs) and cellular senescence markers and simultaneously increased fibroblast proliferation and collagen production.

Reprogramming with Turn Bio's ERA technology can rejuvenate cells within the extracellular matrix (ECM), resulting in changes related to improved skin quality and structure, according to a presentation at the AAD 2023 Innovation Academy in Tampa, Fla.

ERA reprogramming technology significantly reduced oxidative stress, matrix metalloproteinases (MMPs) and cellular senescence markers and simultaneously increased fibroblast proliferation and collagen production, according to Edward Hsia, PhD, vice president of Dermatology at Turn Bio.

"The AAD's decision to introduce a session exploring the potential impact of regenerative medicine on dermatologic treatments acknowledges the importance of these new therapies, including the promise of Turn Bio's ERA technology," says Joely Kaufman, MD, FAAD, a  dermatologist and director of Skin Associates of South Florida, in Coral Gables, Fla, who co-directed the session in which Turn Bio presented its data, in a news release. "We are on the verge of significantly improving standards of care for many conditions. The potential is incredible for both patients and practitioners." 

This regenerative medicine session was a first for the AAD.

"It is an honor for Turn Bio to be included in the inaugural regenerative medicine session at the AAD 2023 Innovation Academy," says Turn Bio CEO Anja Krammer. "We are thrilled to be sharing our research in epigenetic reprogramming for cell rejuvenation and showing the possibilites in dermatological treatments for patients in the future."